Skip to main content

Advertisement

SpringerLink
Log in

Clinical study of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B

温针灸联合恩替卡韦治疗慢性乙肝肝硬化代偿期临床研究

  • Clinical Study
  • Published:
Journal of Acupuncture and Tuina Science Aims and scope Submit manuscript

Abstract

Objective

To investigate the efficacy and possible mechanism of action of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B (CHB).

Methods

Ninety patients were randomly divided into a control group and an observation group, with 45 patients in each group. The control group was given oral entecavir, and the observation group was given additional warm needling moxibustion. The serum alanine transaminase (ALT), aspartate transaminase (AST), albumin (ALB) levels, portal vein internal diameter, splenic vein internal diameter, spleen thickness, and liver hardness were compared before and after treatment. The serum hyaluronic acid (HA), laminin (LN), procollagen type III (PCIII), type IV collagen (IV-C), interleukin (IL)-21, and platelet-derived growth factor (PDGF) levels were also measured.

Results

After treatment, the serum ALT and AST levels decreased (P<0.05), and the serum ALB levels increased (P<0.05) in both groups. The serum ALT and AST levels were lower in the observation group than in the control group (P<0.05), and the ALB level was higher in the observation group (P<0.05). The portal vein internal diameter, splenic vein internal diameter, spleen thickness, and liver hardness values were reduced in both groups after treatment (P<0.05), and were lower in the observation group than in the control group (P<0.05). The serum HA, LN, PCIII, and IV-C levels were reduced in both groups (P<0.05), and were lower in the observation group than in the control group (P<0.05). In the control group, the serum IL-21 level decreased (P<0.05), but the serum PDGF level did not change significantly (P>0.05); in the observation group, the serum IL-21 and PDGF levels decreased significantly (P<0.05) and were lower than those in the control group (P<0.05).

Conclusion

Warm needling moxibustion combined with entecavir treatment can improve liver function, reduce the inner diameters of the portal vein and splenic vein, spleen thickness, and liver hardness, and improve liver fibrosis indicators in patients with CHB cirrhosis, which may be related to the reduction of serum IL-21 and PDGF levels.

摘要

目的

探讨温针灸联合恩替卡韦治疗慢性乙肝(CHB)肝硬化代偿期的疗效及可能作用机制。

方法

将90例患者 随机分为对照组和观察组, 每组45例。对照组予恩替卡韦口服, 观察组在此基础上加温针灸。比较治疗前后血清丙氨 酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、白蛋白(ALB)水平及门静脉内径、脾静脉内径、脾脏厚度、肝脏硬度 值, 并测定血清透明质酸(HA)、层粘连蛋白(LN)、III型前胶原(PCIII)、IV型胶原(IV-C)及白介素(IL)-21、血小板源性生 长因子(PDGF)水平。

结果

治疗后, 两组血清ALT及AST水平均降低(P<0.05), 血清ALB水平均升高(P<0.05); 观察组血清 ALT及AST水平低于对照组(P<0.05), 血清ALB水平高于对照组(P<0.05)。两组门静脉内径、脾静脉内径、脾脏厚度和肝 脏硬度值均降低(P<0.05), 观察组指标均低于对照组(P<0.05)。两组血清HA、LN、PCIII及IV-C水平均降低(P<0.05), 观 察组指标水平均低于对照组(P<0.05)。对照组血清IL-21水平降低(P<0.05), 血清PDGF水平无明显变化(P>0.05); 观察组 血清IL-21及PDGF水平均明显降低(P<0.05), 且低于对照组(P<0.05)。

结论

温针灸联合恩替卡韦治疗可改善CHB肝硬化 代偿期患者的肝功能, 缩小门静脉、脾静脉内径及脾脏厚度, 降低肝脏硬度, 改善肝纤维化指标, 可能与其降低患者 血清IL-21及PDGF水平有关。

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. ZHOU W C, ZHANG Q B, QIAO L. Pathogenesis of liver cirrhosis. World J Gastroenterol, 2014, 20(23): 7312–7324.

    Article  Google Scholar 

  2. XU C, CHEN J, ZHANG P A. Relationship between diabetes mellitus and cirrhosis risk in chronic hepatitis B patients in Wuhan, China. Med Sci Monit, 2019, 25: 8112–8119.

    Article  CAS  Google Scholar 

  3. YAN Y P, ZHANG W L, SU H X, WANG A H, SHAO Z J, ZHANG Y, HUANG C X. Research progress and challenges for hepatitis B prevention and treatment in China. Zhongguo Redai Yixue, 2019, 19(10): 916–921.

    Google Scholar 

  4. ZHU K L, ZHU X M, ZENG W D, LIANG J X. New development of investigation of epidemiology of hepatitis B. Guangzhou Yiyao, 2010, 41(4): 1–2.

    Google Scholar 

  5. SUN Y M, YOU H. Advances in staging and treatment of hepatitis B cirrhosis. Linchuang Gandanbing Zazhi, 2016, 32(6): 1036–1039.

    CAS  Google Scholar 

  6. ZHANG J W, SHI Y Q, HAN Y. Progress in treatment of liver cirrhosis. Linchuang Gandanbing Zazhi, 2015, 31(3): 465–468.

    CAS  Google Scholar 

  7. YANG J, LAO X T, ZHENG G X, HE Y Y, ZHOU J W. Research progress of acupuncture in the treatment of viral hepatitis B. Sichuan Zhongyi, 2014, 32(2): 178–179.

    Google Scholar 

  8. CHEN X L, WANG K X, JIAO K D. The efficacy of Wenyang Zhushui decoction combined with warm needling moxibustion in treating 39 cases of cirrhotic ascites. Shandong Zhongyi Zazhi, 2012, 31(12): 857–859.

    Google Scholar 

  9. LIU X J, SHEN Y. Thirty-six cases of non-infectious diarrhea in liver cirrhosis treated with warm needling moxibustion. Hubei Zhongyi Zazhi, 2016, 38(4): 63–65.

    CAS  Google Scholar 

  10. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Shiyan He Linchuang Ganranbing Zazhi, 2015, 9(5): 570–589.

    Google Scholar 

  11. Chinese Society of Integrated Traditional Chinese and Western Medicine, Digestive System Diseases Committee. Consensus on the treatment of liver cirrhosis with integrated traditional Chinese and Western medicine. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi, 2011, 19(4): 277–279.

    Google Scholar 

  12. ROMANELLI R G, STASI C. Recent advancements in diagnosis and therapy of liver cirrhosis. Curr Drug Targets, 2016, 17(15): 1804–1817.

    Article  CAS  Google Scholar 

  13. LI B, JI YJ, SHAO Q, ZHU Z, JI D, LI F, CHEN G. Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia. Exp Ther Med, 2015, 10(6): 2180–2186.

    Article  CAS  Google Scholar 

  14. KONG Y Y, WEI W, SHAN S, MA H, OU X J, XU X Y, DUAN Z P, HOU J L, WEI L, YOU H, JIA J D. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis. Ganzang, 2020, 25(2): 123–127.

    Google Scholar 

  15. YIP T C, WONG V W, CHAN H L, TSE Y K, LUI G C, WONG G L. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology, 2020, 158(1): 215–225.

    Article  CAS  Google Scholar 

  16. TSAI M C, YU H C, HUNG C H, LEE C M, CHIU K W, LIN M T, TSENG P L, CHANG K C, YEN Y H, CHEN C H, HU T H. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol, 2014, 29(3): 568–575.

    Article  CAS  Google Scholar 

  17. MU D S. Record of traditional Chinese medicine on liver cirrhosis and the survey of syndrome differentiation. Liaoning Zhongyiyao Daxue Xuebao, 2020, 22(6): 129–132.

    Google Scholar 

  18. ZHANG Q. Feasibility analysis and clinical value of the Huoxue Huayu therapy on liver cirrhosis. Zhongyi Linchuang Yanjiu, 2020, 12(16): 112–113.

    CAS  Google Scholar 

  19. SUN Y J. Distribution Pattern of TCM Syndromes of Hepatitis B Cirrhosis (Compensation Period) and Related Research. Changchun: Master Thesis of Changchun University of Chinese Medicine, 2020.

    Google Scholar 

  20. VALLIÈRES F, DUROCHER I, GIRARD D. Biological activities of interleukin (IL)-21 in human monocytes and macrophages. Cell Immunol, 2019, 337: 62–70.

    Article  Google Scholar 

  21. YI B Y, DAN C J, ZHU H X, RAO M. Determination of IL-21 levels in patients with hepatitis B and correlation with liver function-related indicators. Shandong Yiyao, 2009, 49(47): 61–62.

    CAS  Google Scholar 

  22. FENG G, ZHANG J Y, ZENG Q L, YU X, ZHANG Z, LÜ S, XU X, WANG F S. Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells. Hepatol Res, 2014, 44(10): 198–205.

    Article  Google Scholar 

  23. LIU D X, ZOU X X, ZHU X, LIU Y, GUO Y J. Influence of disconnection on serum PDGF, CTGF and liver fibrosis four items of patients with hepatitis B liver cirrhosis. Yixue Zongshu, 2016, 22(6): 1237–1239.

    Google Scholar 

  24. LÜ J, ZHANG H, WANG L. Study progress of the molecular mechanisms and therapies of liver fibrosis. Zhongguo Yiyuan Yaoxue Zazhi, 2017, 37(18): 1873–1876.

    Google Scholar 

Download references

Acknowledgments

There was no project fund support for this study.

Author information

Authors and Affiliations

  1. Hubei Provincial Hospital of TCM, Wuhan, 430060, China

    Lu Nie  (聂璐) & Juanli Zhang  (张娟丽)

Authors
  1. Lu Nie  (聂璐)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juanli Zhang  (张娟丽)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juanli Zhang  (张娟丽).

Additional information

Conflict of Interest

The authors declare that there is no potential conflict of interest in this article.

Statement of Informed Consent

Informed consent was obtained from all individual participants.

First Author: NIE Lu, bachelor, attending physician

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, L., Zhang, J. Clinical study of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B. J. Acupunct. Tuina. Sci. 20, 199–205 (2022). https://doi.org/10.1007/s11726-022-1313-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11726-022-1313-9

Keywords

关键词

中图分类号

文献标志码

Search

Navigation